Zydus Lifesciences’ Q1 FY26 net profit rose 3% YoY to ₹1,467 crore, driven by growth in domestic and international markets.
Revenue from operations increased 6% YoY to ₹6,574 crore, with most key businesses meeting expectations.
Domestic business revenue grew 6% YoY to ₹2,374 crore.
Consumer wellness revenue inched up 2% to ₹855 crore.
Zydus Lifesciences on Tuesday said its consolidated net profit increased 3% year-on-year to ₹1,467 crore for the first quarter ended June 30, 2025, riding on strong performance across domestic and international markets.
The drug maker reported a net profit of ₹1,420 crore for the April-June quarter of the last fiscal.
Revenue from operations rose to ₹6,574 crore for the June quarter as compared with ₹6,207 crore in the year-ago period, the drug maker said in a statement.
"Our Q1 FY2026 performance reflects the results of our disciplined execution, with most of our key businesses meeting expectations," Zydus Lifesciences MD Sharvil Patel said.
The company remains firmly on track to achieve FY2026 aspirations and is excited about the upcoming developments on the innovation front, which will open up new avenues for sustainable growth, he added.
The drug maker said its domestic business revenue increased 6 per cent year-on-year to ₹2,374 crore in the June quarter.
Revenues of the formulations business saw a growth of 8% year-on-year to ₹1,519 crore in the year-ago period.
Consumer wellness business revenue grew 2% year-on-year to ₹855 crore in the first quarter ended June 30, 2025.
US formulations business revenue grew 3% year-on-year to ₹3,182 crore in the June quarter.
Shares of the company on Tuesday ended 0.27% up at ₹958.05 apiece on BSE.
